États-Unis · Magazines éco · Axios Markets

Blackstone is becoming a biotech bank

Publié par Axios Markets · États-Unis il y a 1 j

Résumé détaillé

Why it matters: Blackstone has become something akin to a biotech bank, helping offset drug development costs for Pfizer, Apogee, Alnylam, Boston Scientific, J&J, Merck, and…

Lire l'article complet sur Axios Markets Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.axios.com)

Blackstone is becoming a biotech bank

Résumé détaillé

À lire aussi

A warning for the new Congress: Don’t stop at ‘affordability’

4 Money Lessons to Learn From Financially Solo Adults

McLaren Listened to Its Customers. The Result Is a Supercar With This 1 Beloved Feature

Here’s how to fix the looming Social Security shortfall

Study Finds 1.2 Million People Use Cannabis Daily In Great Britain

You’re Not Behind on AI Agents Yet. Learn How They Work in 10 Minutes, Before Your Competitors Get Ahead

Blackstone is becoming a biotech bank

Résumé détaillé

Partager

À lire aussi

A warning for the new Congress: Don’t stop at ‘affordability’

4 Money Lessons to Learn From Financially Solo Adults

McLaren Listened to Its Customers. The Result Is a Supercar With This 1 Beloved Feature

Here’s how to fix the looming Social Security shortfall

Study Finds 1.2 Million People Use Cannabis Daily In Great Britain

You’re Not Behind on AI Agents Yet. Learn How They Work in 10 Minutes, Before Your Competitors Get Ahead